TheraVitae Presents Stem Cell Research Innovations at Toronto Stem Cell Conference

A poster presentation outlining the latest advances in its ongoing research into blood-borne stem cell biology and its clinical applications was given by Dr. Yael Porat, Vice-President of Research & Development, TheraVitae Ltd., at the 4th International Society for Stem Cell Research (ISSCR) meeting in Toronto, Canada.

The presentation focused on the company’s advances in its ongoing research into blood-borne stem cell biology and its clinical applications.

The highlight was the discovery of unique stem cell populations, which TheraVitae’s researchers have isolated from human blood, and their potential to turn into different tissues in-vitro.

The ability to obtain this population directly from blood using a simple, painless and rapid isolation process constitutes a major breakthrough in adult stem cell research and builds on the clinical success that VesCell™ - adult stem cell therapy for heart disease, has already demonstrated.

Outlining the reason for developing this line of research, Dr. Porat said, "Blood cells are a very accessible source of progenitor cells and their potential to generate a variety of cell types appears endless."

"Our goal is to push the boundaries of stem cell science by constantly developing new therapeutic cellular products."

The presentation 'Synergetic Cell Population: A Multipotent Human Blood-Derived Cell Population as a Potential Source of Therapeutic Progenitor Cells' described the use of TheraVitae’s core technology.

The method of isolation of this distinctive cell population residing in the peripheral blood can lead to the development of treatments for a variety of diseases using the patient’s own cells.

TheraVitae aims to one day provide effective treatments for patients suffering from hitherto incurable diseases, and according to Dr. Porat, the advances that were presented at the ISSCR meeting, constitute a big step towards achieving the development of additional autologous adult stem cell therapeutic products.

Dr. Valentin Fulga, CEO of TheraVitae lauded the research team and thanked the ISSCR, "It is due to Yael and her team’s efforts that our company’s research results are being recognized by the International scientific community."

"We are grateful to the ISSCR for accepting the abstract for presentation and I am convinced that Dr. Porat’s dedication and hard work will continue to provide breakthroughs that we can present at future ISSCR meetings."